Managing and avoiding bortezomib toxicity

Community Oncology

Volumn 4, Issue 8, 2007, Pages 480-484

  Menashe, Jeffrey ^a  

^a Northwest Cancer Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DULOXETINE; ERYTHROMYCIN; GABAPENTIN; GLUTAMINE; KETOCONAZOLE; MELPHALAN; METHYLPHENIDATE; MINERALOCORTICOID; MODAFINIL; PREDNISONE; PROTEASOME INHIBITOR; PYRIDOXINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ARTHRALGIA; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; EDEMA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INSOMNIA; KIDNEY DISEASE; LIMB PAIN; MALAISE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA; UNITED STATES; VOMITING; WEAKNESS;

EID: 35348988646     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70481-8     Document Type: Review

References (18)

1. Aghajanian C, Soignet S, Dixon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. J Clin Oncol 2002;8:2505-2511.
2. Reinstein E, Ciechanover A. Protein degradation and human diseases: the ubiquitin connection [review]., Ann Intern Med 2006;145:676-684.
3. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:2377-2380.
4. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18 (epub doi: 10.1186/1475-2867-5-18).
5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
6. Velcade [prescribing information]. Cambridge, Mass: Millennium Pharmaceuticals, Inc; 2004.
7. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
8. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
9. Sezer O, Vesole D, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006;7:233-235.
10. Berenson J, Yang H, Swift R, et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood 2004;104(11):209.
11. Palumbo A, Ambrosini M, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed myeloma. Blood 2007;109(11):2767.
12. Alexanian R, Wang L, Weber D, et al. VTD as primary therapy for newly diagnosed multiple myeloma. Blood 2004;104(11):210.
13. Jagannath S, Barlogie B, Berenson J, et al. Bortezomib in recurrent and/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195-1200.
14. San Miguel JF, Richardson P, Sonneveld P, et al. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 2005;106:366.
15. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-3120.
16. Lonial S, Waller EK, Richardson PG, et al. Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma. Blood 2003;102(11):1632.
17. Lee S, Richardson PG, Barlogie B, et al. Quality of life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol 2003;22:2339.
18. Suvannasankah A, Smith G, Juliar B, et al. Weekly bortezomib/ methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 2006;7:131-134.